Skip to main navigation Skip to search Skip to main content

A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma

  • Tejaswi V. Mudigonda
  • , Kenneth Wyman
  • , David R. Spigel
  • , Kimberly B. Dahlman
  • , F. Anthony Greco
  • , Igor Puzanov
  • , Mark C. Kelley
  • , John D. Hainsworth
  • , Jeffrey A. Sosman
  • , Douglas B. Johnson
  • Vanderbilt University
  • Sarah Cannon Research Institute

Research output: Contribution to journalArticlepeer-review

16 Scopus citations
Original languageEnglish
Pages (from-to)101-103
Number of pages3
JournalPigment Cell and Melanoma Research
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Dive into the research topics of 'A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma'. Together they form a unique fingerprint.

Cite this